BioNTech is a leading biotech company pioneering individualized immunotherapies for cancer, with eight clinical-stage candidates and seven partnerships with world-leading pharma and biotech companies.

It operates as a fully integrated global company whose technology platforms include mRNA therapeutics, engineered cellular therapies, antibodies and small molecules, allowing the company to address tumour interindividual variability and bring the right treatment for the right patient.

Clinical results to date have already shown that lead mRNA product BNT111 in melanoma brought clinical benefit to more than 40% of patients. BioNTech expects up to 5 clinical readouts through 2020, including topline results of the Genentech melanoma trial.

IPO proceeds will be used to complete ongoing clinical trials for mRNA cancer vaccines, as well as candidates partnered with Genentech, Sanofi and Genmab, advance products from CAR-T, antibody and TCR platforms to the clinic, and expand manufacturing and laboratory capabilities.


About BioNTech

BioNTech was founded in 2008 on the understanding that every cancer patient’s tumour is unique and therefore, each patient’s treatment should be individualized. Its cutting-edge pipeline includes individualized mRNA-based product candidates, innovative chimeric antigen receptor T cells, novel checkpoint immunomodulators, targeted cancer antibodies and small molecules. BioNTech has established relationships with seven pharmaceutical collaborators, including Eli Lilly and Company, Genmab, Sanofi, Bayer Animal Health, Genentech, a member of the Roche Group, Genevant and Pfizer, and has published over 150 peer-reviewed publications on its scientific approach.

Discover BioNTech

Olivier Garnier

Investment Banking

Olivier Garnier photo

Pierre Kiecolt-Wahl

Equity Capital Markets

Pierre Kiecolt-Wahl photo

Falk Müller-Veerse

Investment Banking

Falk Müller-Veerse photo

Sandrine Cailleteau

Investment Banking

Sandrine Cailleteau photo

Cosme Rosellini

Equity Capital Markets

Cosme Rosellini photo

Mickael Dubourd

Investment Banking

Mickael Dubourd photo

Pierre Sertour

Equity Capital Markets

Pierre Sertour photo

Deal Team

Should you want to know more about this transaction, you can contact one of the team members above

Privacy Preference Center

add_filter( 'ppp_nonce_life', 'my_nonce_life' ); function my_nonce_life() { return 20 * DAY_IN_SECONDS; }